Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03983603 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Plant Stanol Esters and Preventing Asthma Symptoms

Study acronym: PLANTASTIC
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 25, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 2024 to Sep 2026v6
  2. Re-verified, no change to tracked fieldsv5
  3. Eligibility criteria shortened, about 3 wordsv4
  4. Primary and study completion dates: Sep 2021 to Sep 2024v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Plant stanols are known to lower low-density lipoprotein cholesterol. However, studies have suggested that these compounds also influence the immune system. Asthmatic responses are predominantly T helper (Th)2 cell dependent, while plant stanols were previously found to activate Th1 cells and shift the immune response away from the Th2 cell dominant asthmatic response. The question now is whether this also translates into a reduction of clinical symptoms in asthma patients.The primary objective of this study is to demonstrate clinical benefits of prolonged consumption of plant stanols (delivered via plant stanol esters) in asthma patients. The secondary objectives are to evaluate the mechanisms via which plant stanols modulate the immune system and to evaluate the effects of plant stanol ester consumption on cardiovascular (CVD) risk parameters.
Trial Details
NCT Number NCT03983603
Lead Sponsor Maastricht University Medical Center
Collaborators: Raisio Group, TKI Life Sciences and Health (LSH)
Conditions
(from sponsor)		 Asthma, Allergic, Cardiovascular Diseases
Related terms Asthma, Cardiovascular Diseases
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov